Evaluating Pharmacological and Rehabilitation Strategies for Effective Management of Bipolar Disorder: A Comprehensive Clinical Study DOI Open Access
Rocco de Filippis, Abdullah Al Foysal

Advances in Bioscience and Biotechnology, Journal Year: 2024, Volume and Issue: 15(07), P. 406 - 431

Published: Jan. 1, 2024

Bipolar disorder presents significant challenges in clinical management, characterized by recurrent episodes of depression and mania often accompanied impairment functioning. This study investigates the efficacy pharmacological interventions rehabilitation strategies to improve patient outcomes quality life. Utilizing a randomized controlled trial with multiple treatment arms, participants will receive pharmacotherapy, polypharmacotherapy, interventions, or combination treatments. Outcome measures be assessed using standardized scales, including Hamilton Depression Scale, Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Mania Scale. Preliminary data suggest improvements symptom severity functional research aims inform practice, guide decisions, ultimately enhance care for individuals living bipolar disorder. Findings disseminated through peer-reviewed journals scientific conferences advance knowledge this field.

Language: Английский

The immunological perspective of major depressive disorder: unveiling the interactions between central and peripheral immune mechanisms DOI Creative Commons
Jiao Wang, Jiayi Lin,

Yanfang Deng

et al.

Journal of Neuroinflammation, Journal Year: 2025, Volume and Issue: 22(1)

Published: Jan. 19, 2025

Major depressive disorder is a prevalent mental disorder, yet its pathogenesis remains poorly understood. Accumulating evidence implicates dysregulated immune mechanisms as key contributors to disorders. This review elucidates the complex interplay between peripheral and central components underlying pathology. Peripherally, systemic inflammation, gut dysregulation, dysfunction in organs including gut, liver, spleen adipose tissue influence brain function through neural molecular pathways. Within nervous system, aberrant microglial astrocytes activation, cytokine imbalances, compromised blood-brain barrier integrity propagate neuroinflammation, disrupting neurotransmission, impairing neuroplasticity, promoting neuronal injury. The crosstalk immunity creates vicious cycle exacerbating neuropathology. Unraveling these multifaceted immune-mediated provides insights into major disorder's pathogenic basis potential biomarkers targets. Modulating both responses represent promising multidimensional therapeutic strategy.

Language: Английский

Citations

5
GDNF improves the cognitive ability of PD mice by promoting glycosylation and membrane distribution of DAT DOI Creative Commons

Ma Chengcheng,

An Panpan,

Yan Yalong

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Aug. 1, 2024

Abstract The core of clinic treatment Parkinson's disease (PD) is to enhance dopamine (DA) signaling within the brain. regulation transporter (DAT) integral this process. This study aims explore regulatory mechanism glial cell line-derived neurotrophic factor (GDNF) on DAT, thereby gaining a profound understanding its potential value in treating PD. In study, we investigated effects GDNF both cellular and mouse models PD, including glycosylation membrane transport DAT detected by immunofluorescence immunoblotting, DA signal measured neurotransmitter fiber imaging technology, Golgi morphology observed electron microscopic, as well cognitive ability assessed behavior tests. revealed that animal trials, MPTP-induced Disease mice exhibited marked decline function. Utilizing ELISA techniques, decrease levels significant reduction intensity release Prefrontal Cortex (PFC) PD induced MPTP. Intriguingly, these alterations were reversed Glial Cell Line-Derived Neurotrophic Factor (GDNF). experiments, following MPP + intervention, there was Gly-DAT modification cytoplasm, coupled with an increase Nongly-DAT expression aggregation cytoplasm. Conversely, augmented facilitated damaged dopaminergic neurons, concurrently reversing GRASP65 depletion fragmentation, reducing accumulation apparatus. Furthermore, overexpression enhanced cells mice, while suppression attenuated efficacy DAT. Additionally, potentiated reutilization neurotransmitters PFC presynaptic membrane, boosting effective single electrical stimulation, ultimately ameliorating impairments mice.Therefore, propose enhances trafficking facilitating re-aggregation apparatus, amplifying utilization signals. leads improvement abilities models. Our illuminates, from novel angle, beneficial role augmenting function providing fresh insights into therapeutic potential.

Language: Английский

Citations

4
Intermittent fasting produces antidepressant-like effects by modulating dopamine D1 receptors in the medial prefrontal cortex DOI Creative Commons

Jingjing Piao,

Hongyu Chen,

X. S. Piao

et al.

Neurobiology of Disease, Journal Year: 2025, Volume and Issue: 211, P. 106931 - 106931

Published: April 30, 2025

Nutritional psychiatry has gained increasing attention, particularly in exploring dietary interventions for depression treatment. As a potential non-drug intervention, intermittent fasting (IF) gradually attracted the interest of researchers, but its specific neurobiological mechanisms remain unclear. The medial prefrontal cortex (mPFC) dopamine D1 receptors (Drd1) are significant stress response and serve as molecular target rapid-acting antidepressants. Our previous study indicated that 9-h produces an antidepressant-like effect by modulating (DA) receptors. However, whether IF effects through actions on DA receptor-mediated remains Here, we investigated improving depression-like behavior induced Chronic Unpredictable Mild Stress (CUMS) mice explored these regulated Drd1. We found alleviated CUMS-induced behavior, increased c-Fos expression mPFC hippocampus CUMS mice, activated Drd1-cAMP-PKA-DARPP-32-CREB-BDNF signaling pathway. were reversed Drd1 antagonist SCH23390. Additionally, optogenetic activation Drd1-expressing neurons improved while inhibition suppressed IF-induced effects. These findings imply plays crucial role offer valuable insights into application clinical

Language: Английский

Citations

0
The role of enteric nervous system and GDNF in depression: conversation between the brain and the gut DOI
Chao Liang, Sijia Wei,

Yelin Ji

et al.

Neuroscience & Biobehavioral Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 105931 - 105931

Published: Oct. 1, 2024

Language: Английский

Citations

1
GDNF improves the cognitive ability of PD mice by promoting glycosylation and membrane distribution of DAT DOI Creative Commons
Chengcheng Ma,

Panpan An,

Yalong Yan

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: March 29, 2024

Abstract The core of clinic treatment Parkinson's disease (PD) is to enhance dopamine (DA) signaling within the brain. regulation transporter (DAT) integral this process. This study aims explore regulatory mechanism glial cell line-derived neurotrophic factor (GDNF) on DAT, thereby gaining a profound understanding its potential value in treating PD. Here, we investigated effects GDNF both cells and mice with PD, including glycosylation membrane distribution DAT detected by immunofluorescence immunoblotting, DA signal measured neurotransmitter fiber imaging technology, Golgi morphology observed electron microscopic, as well cognitive ability assessed behavior tests. In study, enhanced injured neurons vivo invitro, while reversing GRASP65 loss fragmentation leading alleviation accumulation Golgi. Moreover, overexpression increased PD mice, whereas, inhibition could diminished role DAT. addition, reutilization uptake presynaptic membranes PFC effective release after single electrical stimulation, ultimately improving impairment mice. Thus, proposed that promotes facilitating reaggregation, an enhancement utilization, resulting improvement illustrates from new perspective beneficial enhancing utilization cognition

Language: Английский

Citations

0
Evaluating Pharmacological and Rehabilitation Strategies for Effective Management of Bipolar Disorder: A Comprehensive Clinical Study DOI Open Access
Rocco de Filippis, Abdullah Al Foysal

Advances in Bioscience and Biotechnology, Journal Year: 2024, Volume and Issue: 15(07), P. 406 - 431

Published: Jan. 1, 2024

Bipolar disorder presents significant challenges in clinical management, characterized by recurrent episodes of depression and mania often accompanied impairment functioning. This study investigates the efficacy pharmacological interventions rehabilitation strategies to improve patient outcomes quality life. Utilizing a randomized controlled trial with multiple treatment arms, participants will receive pharmacotherapy, polypharmacotherapy, interventions, or combination treatments. Outcome measures be assessed using standardized scales, including Hamilton Depression Scale, Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Mania Scale. Preliminary data suggest improvements symptom severity functional research aims inform practice, guide decisions, ultimately enhance care for individuals living bipolar disorder. Findings disseminated through peer-reviewed journals scientific conferences advance knowledge this field.

Language: Английский

Citations

0